NSI-189

NSI-189, also known as amdiglurax, is an investigational, orally active neurogenic compound originally developed by Neuralstem for research into major depressive disorder and neurological dysfunction. It is a synthetic small molecule belonging to the benzylpiperazine-aminopyridine chemical family, rather than a conventional peptide. Its principal research interest involves the stimulation of hippocampal neurogenesis, neuronal development, and synaptic plasticity. Laboratory and animal studies have demonstrated changes in neurogenic factors such as brain-derived neurotrophic factor (BDNF) and stem cell factor (SCF), along with improvements in selected neurological and behavioral models.

NSI-189 has undergone Phase 1b and Phase 2 human clinical trials for major depressive disorder. The small Phase 1b study reported promising improvements in selected depressive and cognitive symptoms, while the larger 220-participant Phase 2 trial did not demonstrate a statistically significant improvement on its primary depression rating scale. However, selected secondary symptom and cognitive measures showed favorable results, particularly at the 40 mg daily dose. Additional preclinical research has explored potential benefits in stroke, radiation-induced cognitive impairment, and diabetic neuropathy. NSI-189 remains investigational, is not FDA-approved, and has no established clinical role in treating depression, memory impairment, or neurological disease.

NSI-189 is being investigated for its effects on hippocampal neurogenesis, neuronal survival, synaptic plasticity, and neurotrophic signaling. Its biological activity has been demonstrated in several experimental systems, although its precise direct molecular target has not been conclusively identified.

1. Hippocampal Neurogenesis

• The hippocampus is involved in memory formation, learning, and emotional regulation.
• Neurogenesis refers to the production and maturation of new neurons from neural precursor cells.
• Preclinical research indicates that NSI-189 can influence neural progenitor proliferation and neuronal maturation.
• Animal studies have reported changes in neurogenesis-related markers and hippocampal structure following treatment.
• Whether NSI-189 meaningfully increases the production of new neurons in the adult human brain remains unknown.

2. Brain-Derived Neurotrophic Factor (BDNF)

• BDNF is a signaling protein involved in neuronal maintenance, synaptic plasticity, and learning-related processes.
• A 2017 study involving experimental stroke demonstrated increased BDNF-related activity in cell models exposed to NSI-189.
• These responses occurred alongside changes in neuronal survival and neurite development.
• BDNF signaling is also implicated in antidepressant treatment research.
• However, increased BDNF expression in an experimental model does not prove clinical antidepressant effectiveness.

3. Stem Cell Factor (SCF) Signaling

• Stem cell factor, also called SCF or KIT ligand, participates in cell survival, proliferation, and differentiation.
• In experimental models of cerebral ischemia, NSI-189 was associated with increased SCF expression.
• This response may contribute to a biological environment supporting neuronal repair and tissue remodeling.
• SCF has widespread functions outside the nervous system, and the systemic consequences of modifying its signaling require further investigation.

4. TrkB and Receptor Tyrosine Kinase Signaling

• TrkB is a receptor tyrosine kinase that responds to BDNF.
• Activation of TrkB can influence intracellular signaling associated with neuronal survival and plasticity.
• NSI-189 is frequently categorized commercially alongside compounds associated with BDNF and Trk signaling.
• However, a 2021 experimental screening study did not identify direct binding of NSI-189 to the extracellular TrkB receptor.
• The same research did not establish direct TrkB activation by NSI-189.
• Consequently, NSI-189 should not be described as a proven direct TrkB receptor agonist.

5. Synaptic Plasticity and Long-Term Potentiation

• Synaptic plasticity refers to changes in the strength and function of communication between neurons.
• Long-term potentiation (LTP) is an experimental model of sustained strengthening of synaptic connections.
• A study involving hippocampal brain slices from mice demonstrated enhanced LTP following exposure to NSI-189.
• Researchers also observed improvements in selected cognitive and motor behaviors in a mouse model of Angelman syndrome.
• These findings support research into synaptic function but do not establish improved cognition in healthy humans.

6. Neurite Outgrowth and Neuronal Remodeling

• Neurites are extensions of neurons that contribute to communication among nerve cells.
• MAP2 is a protein associated with neuronal structure and dendritic development.
• In a 2017 rat stroke study, NSI-189 treatment increased selected measurements of MAP2-related neuronal remodeling.
• Changes were particularly evident in the hippocampus and portions of the cerebral cortex.
• These results suggest structural adaptation following injury rather than definitive regeneration of damaged human brain tissue.

7. Neuroprotection Following Cerebral Ischemia

• Cerebral ischemia occurs when brain tissue receives insufficient blood flow and oxygen.
• Ischemic injury can trigger inflammation, oxidative stress, mitochondrial dysfunction, and neuronal death.
• Experimental NSI-189 treatment reduced selected injury-related measurements in rat brain and cell models.
• Researchers observed improvements in neurological behavior even when treatment began several hours after experimental stroke.
• These findings do not establish effectiveness in human stroke treatment or replace established emergency interventions.

8. Neuroinflammation and Microglial Activity

• Microglia are immune-related cells involved in brain maintenance and inflammatory responses.
• A 2018 study investigated NSI-189 in rats with radiation-induced cognitive dysfunction.
• Treatment was associated with fewer activated microglia and improvements in selected cognitive tasks.
• The effects suggest possible interactions between neurogenesis and neuroinflammatory signaling.
• Direct anti-inflammatory therapeutic effects in humans remain unproven.

9. Mitochondrial and Peripheral Nerve Research

• Peripheral neurons require substantial metabolic energy to maintain nerve signaling and axonal structure.
• Experiments involving diabetic rodents and cultured sensory neurons demonstrated improvements in neurite outgrowth and mitochondrial respiration.
• NSI-189 also improved selected measures of diabetic peripheral neuropathy in animal models.
• These findings have not been confirmed in human diabetic neuropathy trials.

10. Neurogenesis and Depression

• Some depression models associate chronic stress with changes in hippocampal function and neuronal plasticity.
• NSI-189 was developed partly around the hypothesis that enhancing neurogenic processes could improve depressive symptoms.
• A small Phase 1b trial reported encouraging symptom changes.
• However, the larger Phase 2 clinical trial failed to demonstrate a statistically significant effect on its primary depression scale.
• This result demonstrates that promising neurogenic mechanisms do not necessarily translate into effective antidepressant treatment.

The Key Difference: NSI-189 is a neurogenic research compound with multiple demonstrated preclinical effects. However, its direct molecular target remains unresolved, its TrkB agonism has not been established, and its biological activity does not guarantee clinical improvement in depression or cognition.

Researchers are interested in NSI-189 because it represents an experimental approach to neurological treatment based on neuronal growth and plasticity rather than conventional monoamine reuptake inhibition.

• Major Depressive Disorder: Phase 1b and Phase 2 studies evaluated its potential antidepressant activity.
• Hippocampal Neurogenesis: Preclinical experiments demonstrated effects on neuronal precursor cells and neurogenesis-related pathways.
• BDNF and SCF: Experimental stroke research identified changes in these growth factors.
• Memory and Cognition: Selected clinical secondary outcomes and animal studies suggest possible cognitive effects.
• Synaptic Plasticity: Hippocampal experiments demonstrated enhancement of long-term potentiation.
• Stroke Recovery: Rat research demonstrated improved neurological function following cerebral ischemia.
• Radiation-Related Cognitive Impairment: Animal studies reported improvement in selected memory tasks after cranial irradiation.
• Diabetic Neuropathy: Preclinical experiments demonstrated effects on peripheral nerve function and hippocampal outcomes.
• Neuroinflammation: Research identified changes in activated microglia and inflammatory responses.
• Novel Drug Development: NSI-189 provides a model for investigating neurological activity without relying primarily on traditional serotonin or norepinephrine reuptake inhibition.

Research Limitation: The Phase 2 depression trial did not meet its primary efficacy endpoint. Findings involving cognitive function, neurogenesis, and neurological recovery require additional independent confirmation before clinical benefits can be established.

NSI-189 has demonstrated neurogenic and neurological activity in preclinical studies and has undergone controlled human investigation for major depressive disorder. The clinical results are mixed, with promising early outcomes but failure to meet the primary efficacy endpoint in the larger Phase 2 trial.

Key Human Clinical Findings

Phase 1b — Encouraging Early Results: The randomized, double-blind, placebo-controlled Phase 1b trial enrolled 24 adults with major depressive disorder. Researchers evaluated 40 mg once daily, twice daily, or three times daily for 28 days. Exploratory outcomes showed favorable changes in selected depression and cognitive-function questionnaires, with effects continuing during follow-up after treatment stopped. The study was too small to establish antidepressant effectiveness.

Phase 2 — Primary Endpoint Failure: The larger Phase 2 study randomized 220 participants to NSI-189 40 mg/day, 80 mg/day, or placebo. Neither dose achieved a statistically significant improvement over placebo on the Montgomery-Asberg Depression Rating Scale (MADRS), the prespecified primary outcome.

Phase 2 Numerical Results: The pooled estimated MADRS difference versus placebo was approximately -1.8 points for 40 mg/day (p=0.22) and -1.4 points for 80 mg/day (p=0.34). These results did not meet conventional statistical significance.

Patient-Reported Secondary Outcomes: At 40 mg/day, researchers reported improvements on the Symptoms of Depression Questionnaire (SDQ; p=0.04) and Cognitive and Physical Functioning Questionnaire (CPFQ; p=0.03). These were secondary findings and should not override the negative primary outcome.

Objective Cognitive Testing: Several CogScreen measures showed favorable results at 40 mg/day, with individual statistically significant comparisons. However, the separate Cogstate testing battery did not demonstrate significant treatment differences.

Post-Hoc Depression Analysis: A later analysis identified possible benefits in selected participants with moderate rather than severe baseline depression. Because these subgroup findings were exploratory and derived from the same original trial, they cannot be treated as independent clinical confirmation.

Human Hippocampal Volume: Phase 1b brain-imaging measurements did not demonstrate a statistically significant increase in hippocampal volume. The research therefore does not establish that NSI-189 grows the human hippocampus.

Experimental Stroke Recovery: A 2017 study found that rats receiving oral NSI-189 after ischemic stroke showed improved selected motor and neurological outcomes. Treatment also influenced neuronal remodeling and BDNF/SCF-related cellular responses.

Radiation-Induced Cognitive Dysfunction: A 2018 rat study reported improved performance on four exploratory memory tasks, along with increased neurogenesis and reduced activated microglia. Hippocampal volume did not significantly increase in this experimental model.

Diabetic Neuropathy: A 2019 study involving mouse models of type 1 and type 2 diabetes reported improvements in selected peripheral nerve measurements, hippocampal neurogenesis, and memory-related function.

Research Perspective: NSI-189 has demonstrated biological activity and potential neurological benefits in multiple preclinical models. Its human antidepressant evidence is mixed, and no adequate clinical evidence establishes cognitive enhancement in healthy adults, stroke recovery, or treatment of neurodegenerative disease.

NSI-189 has been evaluated in human clinical trials using oral administration. The most extensively studied pharmaceutical form is NSI-189 phosphate. Published clinical studies establish specific experimental doses, but no FDA-approved dosing regimen exists for depression, cognitive enhancement, or neurological disease.

Published Clinical Dosing and Community-Reported Amounts

Administration Considerations:

• Oral Administration: The primary route used in published human clinical trials.
• Pharmaceutical Form: NSI-189 phosphate was the form evaluated in the major published depression studies.
• Free Base Versus Phosphate: NSI-189 free base has a molecular weight of approximately 366.5 g/mol, compared with 464.5 g/mol for the phosphate form. Equal masses therefore do not contain equal quantities of active NSI-189 molecules.
• Absorption: Human Phase 1b research found that peak plasma concentrations generally occurred approximately one to two hours after administration.
• Half-Life: The measured human elimination half-life ranged from approximately 17.4 to 20.5 hours.
• Steady State: Phase 1b researchers observed steady-state exposure after approximately four to five days.
• Frequency: Once-daily and divided-dose regimens were studied. No schedule is clinically validated for healthy-adult cognitive enhancement.
• Sublingual Administration: Sometimes discussed informally, but comparative pharmacokinetic and clinical evidence is insufficient.
• Intranasal Administration: No established human clinical dose or delivery system exists.
• Subcutaneous / Intramuscular Administration: No validated clinical administration regimen has been established.
• Reconstitution: NSI-189 is a small molecule investigated orally. It does not require bacteriostatic water or injectable preparation for the studied route.
• Storage: Research-grade products should follow formulation-specific manufacturer stability information. No universal consumer storage specification or expiration period exists.

Phase 1b Dose-Escalation Distinction: Administration of up to 120 mg daily for 28 days in a small closely monitored study does not establish that 120 mg is safe for unsupervised use or more effective than lower doses.

Phase 2 Dose-Response Finding: The 80 mg/day group did not show superior antidepressant effectiveness compared with the 40 mg/day group. Neither dose achieved the study's primary efficacy endpoint.

Animal-to-Human Translation: Experimental animal doses expressed in mg/kg cannot be directly converted into safe human regimens. Species differences in absorption, metabolism, distribution, and neurological response must be considered.

Research Perspective: The quantities above distinguish published clinical exposure from informal community practices. No FDA-approved dose or clinically validated schedule exists for NSI-189, and the reported amounts are not treatment recommendations.

NSI-189 was developed for investigation as a daily oral medication rather than a short-course injectable peptide. Published human clinical research evaluated treatment periods of four to twelve weeks, while longer animal experiments examined neurological recovery after injury.

• Phase 1b Clinical Research: Evaluated 28 days of oral treatment followed by additional observation through approximately day 84.
• Phase 2 Clinical Research: Evaluated a 12-week treatment period in adults with major depressive disorder.
• 2017 Stroke Research: Rats received oral NSI-189 daily for 12 weeks, with functional outcomes monitored up to 24 weeks following experimental stroke.
• 2018 Radiation Research: Investigated four weeks of oral treatment, with some cognitive benefits persisting after administration stopped.
• Community Short Courses: Approximately two to four weeks are sometimes described.
• Community Extended Courses: Four to twelve weeks of daily use are discussed informally, often borrowing from clinical study durations.
• Community Washout Periods: One to four weeks off are sometimes described, without controlled validation.
• Long-Term Treatment: Safety and effectiveness beyond the studied treatment periods have not been adequately established.

Persisting Effects: The early Phase 1b clinical study reported that selected improvements continued during follow-up after treatment ended. However, the study was small and did not establish permanent neurological changes.

Tolerance and Dependence: No validated human model establishes that cycling prevents neurological tolerance, dependence, or withdrawal. The absence of clear dependence signals in early trials does not prove long-term freedom from these risks.

Research Perspective: No clinical evidence demonstrates that cycling NSI-189 improves cognition, creates lasting neurogenesis, or provides greater long-term safety than a different treatment schedule.

NSI-189 is sometimes discussed alongside other experimental neuropeptides, antidepressants, and cognitive-support interventions. Proposed combinations generally reflect interest in complementary neurotrophic or neurotransmitter pathways rather than controlled human evidence of synergy.

Antidepressant Combination Consideration: The published Phase 2 trial investigated NSI-189 as monotherapy. Its findings do not establish safety or effectiveness when combined with prescription antidepressants.

Neuroplasticity Consideration: Interventions that influence BDNF, synaptic activity, or cell proliferation do not automatically provide additive cognitive benefits when used together.

Research Perspective: No controlled human clinical evidence establishes that stacking NSI-189 with experimental peptides, nootropics, or prescription medications improves neurological outcomes or long-term safety.

NSI-189 has a meaningful but limited human clinical safety database from Phase 1b and Phase 2 depression trials. The studies generally reported acceptable short-term tolerability, but adverse effects involving the nervous system, sleep, gastrointestinal function, and cardiovascular symptoms were observed.

Phase 1b Safety Finding: Across 18 participants receiving NSI-189 phosphate, the most frequently recorded adverse effects included headache, dizziness, somnolence, insomnia, and vivid dreams. The study did not identify serious treatment-related adverse events.

Important Headache Distinction: Headaches occurred in 50% of both the combined NSI-189 and placebo groups in the small Phase 1b trial. This means the observed headache frequency cannot be attributed solely to NSI-189.

Phase 2 Safety Finding: The 220-participant Phase 2 study generally found both investigated doses to be well tolerated. No participant assigned to NSI-189 experienced a serious adverse event in that trial, and discontinuation for intolerance was uncommon.

Long-Term Consideration: The absence of serious adverse events in trials lasting four to twelve weeks does not establish safety during continuous exposure over multiple years.

Neurological Consideration: NSI-189 influences pathways involved in neuronal survival and plasticity. The consequences of prolonged or repeated modification of these pathways remain incompletely understood.

Research Perspective: NSI-189 has more human tolerability information than many experimental nootropics, but it does not have an established long-term safety profile or comprehensive medication-interaction database.

No FDA-approved contraindication profile exists for NSI-189 because the compound has not completed clinical development. Although early trials demonstrated relatively favorable short-term tolerability, important uncertainties remain regarding psychiatric effects, neurological safety, medication interactions, and long-term exposure.

• Pregnancy and Breastfeeding: Human reproductive, fetal-development, and lactation safety data are insufficient.
• Children and Adolescents: The effects of NSI-189 on the developing nervous system remain unknown.
• Bipolar Disorder: Potential effects on mood activation, mania, and hypomania have not been adequately characterized.
• Psychotic Disorders: Effects on psychiatric stability and psychosis-related symptoms remain uncertain.
• Severe Depression / Suicidal Thoughts: NSI-189 is not an approved antidepressant, and the larger Phase 2 trial did not establish effectiveness on its primary outcome.
• Seizure Disorders: Effects on neuronal excitability and seizure threshold have not been adequately studied.
• Neurological Disease: Preclinical findings do not establish effectiveness for stroke, dementia, Alzheimer's disease, or Parkinson's disease.
• Recent Stroke: Animal findings do not establish that NSI-189 improves human neurological recovery or replaces established stroke treatment.
• Diabetic Neuropathy: Favorable rodent findings do not establish clinical effectiveness or safety in people with diabetes.
• Cardiovascular Conditions: Limited human studies cannot fully characterize effects on heart rhythm, blood pressure, and cardiovascular disease.
• Kidney or Liver Disease: Effects of organ impairment on metabolism, clearance, and long-term exposure remain insufficiently studied.
• Antidepressant Medications: Potential interactions with SSRIs, SNRIs, MAO inhibitors, and other psychiatric medications have not been adequately evaluated.
• Prescription Stimulants: Combined effects on arousal, sleep, mood, and cardiovascular physiology are uncertain.
• Sedatives / Sleep Medications: Additional effects on sleepiness, dizziness, and cognitive function cannot be reliably predicted.
• Concurrent Experimental Neuropeptides: Combining multiple unapproved neurological compounds introduces additional safety uncertainty.
• Unregulated Research Products: The identity, purity, concentration, and pharmaceutical quality of commercial research preparations may vary.

Regulatory Status: NSI-189 is not FDA-approved for major depressive disorder, cognitive enhancement, neurological injury, diabetic neuropathy, or any other medical indication.

Clinical Efficacy Distinction: Although Phase 1b findings were encouraging, the Phase 2 trial failed its primary depression endpoint. Positive secondary outcomes and exploratory subgroup analyses do not establish NSI-189 as an effective antidepressant.

TrkB Mechanism Distinction: NSI-189 should not be classified as a confirmed direct TrkB agonist. Published screening experiments did not demonstrate the expected direct receptor binding and activation.

Medical Consideration: Existing psychiatric treatment should not be discontinued or replaced based on experimental expectations about neurogenesis. Persistent depression, suicidal thoughts, worsening mood, or progressive neurological symptoms require appropriate clinical care.

NSI-189 research has evaluated depression rating scales, cognitive-function measures, human pharmacokinetics, hippocampal imaging, neuronal-growth markers, and general safety. No clinically validated monitoring protocol exists for NSI-189 outside controlled research.

Clinical Trial Measurement: MADRS was the primary efficacy scale in the Phase 2 study, and neither NSI-189 treatment dose achieved a statistically significant advantage over placebo.

Human Neuroimaging Consideration: The Phase 1b study did not establish a significant increase in hippocampal volume despite the compound's neurogenic research rationale.

BDNF and SCF Consideration: These growth factors have broad biological functions. Changes in peripheral levels do not independently establish new-neuron formation or improved brain function.

Neurogenesis Measurement Consideration: Ki67, MAP2, and doublecortin are predominantly research biomarkers. They are not validated clinical tests for determining whether NSI-189 improves cognition in an individual person.

Cognitive Testing Consideration: Practice effects, motivation, sleep, and underlying psychiatric symptoms can influence neuropsychological testing. Controlled study designs are necessary to determine treatment-related effects.

Important Limitation: No blood test, brain-imaging method, biomarker panel, or monitoring interval has been validated to establish the safety or effectiveness of NSI-189 for routine clinical or cognitive-enhancement use.